Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 6 points (0.0%) at 17,548 as of Friday, Nov. 7, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,802 issues advancing vs. 1,173 declining with 159 unchanged. The Drugs industry currently sits down 0.6% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Intercept Pharmaceuticals ( ICPT), down 28.5%, Valeant Pharmaceuticals International ( VRX), down 2.8%, Vertex Pharmaceuticals ( VRTX), down 2.4%, Teva Pharmaceutical Industries ( TEVA), down 2.2% and Illumina ( ILMN), down 1.4%. A company within the industry that increased today was Perrigo ( PRGO), up 1.7%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Shire ( SHPG) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $2.53 (-1.3%) to $197.42 on average volume. Thus far, 776,739 shares of Shire exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $196.64-$199.75 after having opened the day at $199.62 as compared to the previous trading day's close of $199.95. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $39.6 billion and is part of the health care sector. Shares are up 41.5% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Shire Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.